Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting
December 06, 2025 17:30 ET | Source: Fulcrum Therapeutics, Inc. ― Clear…
BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer
Selective Treg modulator gotistobart (BNT316/ONC-392) showed a reduction in the risk of…
Toripalimab Presents Long-Term Survival Benefits as 1st-line Treatment for Advanced Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma Patients
Long-term OS follow-up analysis of JUPITER-02 demonstrates significantly better and clinically meaningful…
IIM Udaipur Hosts ‘Startup Showcase & Pitch Day’ Organized by IIM Udaipur Incubation Centre and Saksham – The Entrepreneurship Cell
UDAIPUR, India, Nov. 12, 2025 /PRNewswire/ -- The Indian Institute of Management Udaipur…
Cell Impact has been awarded gold medal by EcoVadis
KARLSKOGA, Sweden, Nov. 11, 2025 /PRNewswire/ -- Last year, Cell Impact was…
Ernexa Therapeutics to Present at Oxford Globals Cell 2025
Sanjeev Luther, President and CEO to give an oral presentation and participate…
Cell Impact and thyssenkrupp Automation Engineering have entered a cooperation agreement
KARLSKOGA, Sweden, Nov. 6, 2025 /PRNewswire/ -- Cell Impact and thyssenkrupp Automation Engineering have…
Fulcrum Therapeutics to Present New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting
November 03, 2025 16:45 ET | Source: Fulcrum Therapeutics, Inc. ― Pociredir…
Cullinan Therapeutics Shares Additional Preclinical B Cell Depletion Data for CLN-978, Supporting Clinical Development Across Multiple Autoimmune Diseases, at ACR Convergence 2025
October 25, 2025 11:01 ET | Source: Cullinan Therapeutics, Inc. CLN-978 led…
Galapagos Announces Intention to Wind Down Cell Therapy Business as Part of the Companys Ongoing Transformation
Intention follows comprehensive strategic review process and would represent the optimal capital…
